Michael John Tomsicek

Chief Financial Officer, Cubist Pharmaceuticals.

Companies

Acrivon Therapeutics, Inc.Board member Nov 9, 2022 to now¹
Milestone Pharmaceuticals Inc.Board member May 8, 2019 to now²
CRISPR TherapeuticsChief financial officer Nov 13, 2017 to Aug 10, 2021³
AbioMedChief financial officer Jul 20, 2015 to Jul 18, 2017⁴
Cubist PharmaceuticalsChief financial officer Mar 14, 2013 to Jan 21, 2015⁵

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Acrivon Therapeutics, Inc. ACRV9,366 shares⁶$15.9K at $1.70May 18, 2026
Milestone Pharmaceuticals Inc. MIST15,000 shares⁷$10.6K at $0.71Oct 19, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

May 18, 2026Granted 9,366 shares of Acrivon Therapeutics, Inc.⁶
Oct 19, 2022Bought 15,000 shares at $5.32 of Milestone Pharmaceuticals Inc.⁷

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAcrivon Therapeutics, Inc., Board member
2
SEC EDGARMilestone Pharmaceuticals Inc., Board member
3
SEC EDGARCRISPR Therapeutics, Chief financial officer
4
SEC EDGARAbioMed, Chief financial officer
5
SEC EDGARCubist Pharmaceuticals, Chief financial officer
6
SEC EDGARAcrivon Therapeutics, Inc. shares after the filing of May 18, 2026
7
SEC EDGARMilestone Pharmaceuticals Inc. shares after the filing of Oct 19, 2022